eligibility_summary
Adults 18-75 with multiple myeloma (IMWG), ECOG 0-2, at least 12-week life expectancy, measurable disease, normal organ function, and using contraception. Exclude: anti-tumor Chinese patent meds within 2 weeks, targeted/immunotherapy within 3 weeks, study drug allergies, other malignancy within 3 years, unresolved >grade 1 toxicities, major surgery/serious trauma within 4 weeks or planned, thrombotic event within 6 months, substance abuse/mental disorders, severe/uncontrolled disease or investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06700395 tests TQB2029, an injectable bispecific T‑cell–engaging antibody (immunotherapy) for multiple myeloma. Drug/mechanism: TQB2029 simultaneously binds GPRC5D on myeloma plasma cells and CD3 on T cells, forming an immune synapse that activates TCR/CD3 signaling, recruits/activates cytotoxic T lymphocytes, and triggers perforin/granzyme-mediated killing of GPRC5D+ malignant plasma cells. Targets: GPRC5D-expressing myeloma cells, CD3 on CD3+ T cells, pathways include TCR/CD3 activation, immune synapse formation, and cytokine-driven T-cell cytotoxicity. Phase I dose escalation/expansion in China to assess safety, PK/PD, immunogenicity, and preliminary efficacy.